Flurbiprofen
- CAS No.
- 5104-49-4
- Chemical Name:
- Flurbiprofen
- Synonyms
- ANSAID;2-(2-fluorobiphenyl-4-yl)propanoic acid;fp70;ANSIDE;Adfeed;froben;U-27182;Antadys;Cebutid;Stayban
- CBNumber:
- CB7465967
- Molecular Formula:
- C15H13FO2
- Molecular Weight:
- 244.26
- MOL File:
- 5104-49-4.mol
- MSDS File:
- SDS
- Modify Date:
- 2025/1/27 9:38:02
| Melting point | 110-112 °C(lit.) |
|---|---|
| Boiling point | 376.2±30.0 °C(Predicted) |
| Density | 1.1795 (estimate) |
| storage temp. | Sealed in dry,Room Temperature |
| solubility | methanol: soluble50mg/mL |
| pka | pKa 3.80(H2O) (Uncertain) |
| form | White solid |
| color | white to off-white |
| biological source | synthetic |
| Water Solubility | 8mg/L(room temperature) |
| Merck | 14,4199 |
| InChIKey | SYTBZMRGLBWNTM-UHFFFAOYSA-N |
| CAS DataBase Reference | 5104-49-4(CAS DataBase Reference) |
| EPA Substance Registry System | [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-?-methyl- (5104-49-4) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS06 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H301 | |||||||||
| Precautionary statements | P264-P270-P301+P310+P330-P405-P501 | |||||||||
| Hazard Codes | T,C | |||||||||
| Risk Statements | 25-23/24/25 | |||||||||
| Safety Statements | 36/37/39-45 | |||||||||
| RIDADR | UN 2811 6.1/PG 2 | |||||||||
| WGK Germany | 3 | |||||||||
| RTECS | DU8341000 | |||||||||
| HazardClass | 6.1(b) | |||||||||
| PackingGroup | III | |||||||||
| HS Code | 29163990 | |||||||||
| NFPA 704 |
|
Flurbiprofen price More Price(6)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | F8514 | Flurbiprofen cyclooxygenase inhibitor | 5104-49-4 | 1G | ₹8172.88 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | PHR1499 | Flurbiprofen Pharmaceutical Secondary Standard; Certified Reference Material | 5104-49-4 | 500MG | ₹10792.53 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | F8514 | Flurbiprofen cyclooxygenase inhibitor | 5104-49-4 | 5G | ₹27896.03 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | F8514 | Flurbiprofen cyclooxygenase inhibitor | 5104-49-4 | 25G | ₹79325.6 | 2022-06-14 | Buy |
| TCI Chemicals (India) | F0371 | Flurbiprofen | 5104-49-4 | 5G | ₹4800 | 2022-05-26 | Buy |
Flurbiprofen Chemical Properties,Uses,Production
Description
Flurbiprofen synthesis was originally reported in 1974. During a study of the pharmacological properties of a large number of substituted phenylalkanoic acids, including ibuprofen and ibufenac, the most potent were found to be substituted 2-(4-biphenyl)propionic acids. Further toxicological and pharmacological studies indicated that flurbiprofen possessed the most favorable therapeutic profile, so it was selected for further clinical development. It was not marketed until 1987, when it was introduced as the sodium salt as Ocufen, the first topical NSAID indicated for ophthalmic use in the United States. The indication for Ocufen is the same as that for Profenal—that is, to inhibit intraoperative miosis induced by prostaglandins in cataract surgery.
Chemical Properties
White to Off-White Crystalline Solid
Uses
An anti-inflammatory used as an analgesic.
Indications
Flurbiprofen (Ansaid) is indicated for the treatment of rheumatoid arthritis and osteoarthritis. Its half-life, longer than that of many of the NSAIDs, allows for twice daily dosing.The most common adverse effects of flurbiprofen are similar to those of the other acidic NSAIDs. Flurbiprofen inhibits both COX isoforms about equally.
General Description
Flurbiprofen (Ansaid, Ocufen, Froben), is another drug inthis class indicated for both acute and long-term managementof RA and OA but with a more complex mechanism ofaction. Unlike the other drugs in this class, it does not undergochiral inversion (i.e., the conversion of the “inactive”[R]-enantiomer to the active, [S]-enantiomer). Similar to aspirinand other salicylates, both flurbiprofen enantiomersblock COX-2 induction as well as inhibiting the nuclearfactor-κB-mediated polymorphonuclear leukocyte apoptosissignaling; therefore, both enantiomers are believed to contributeequally to its overall anti-inflammatory action.
(R)-flurbiprofen is actually a strong clinical candidate forthe treatment of Alzheimer disease, because it has beenshown to reduce Aβ42 production by human cells.
Biological Activity
Potent inhibitor of cyclooxygenase (IC 50 values are 0.1 and 0.4 μ M for inhibition of human COX-1 and COX-2 respectively). Analgesic, anti-inflammatory and antipyretic in vivo . Inhibits tumor cell growth in vitro and in vivo . Also inhibits fibroblast proliferation in vitro .
Pharmacokinetics
Flurbiprofen is well absorbed after oral administration, with peak plasma levels being attained within 1.5 hours. Food alters the rate of absorption but not the extent of its bioavailability. It is extensively bound to plasma proteins (99%).and has a plasma half-life of 2 to 4 hours. Metabolism is extensive, with 60 to 70% of flurbiprofen and its metabolites being excreted as sulfate and glucuronide conjugates. Flurbiprofen shows some interesting metabolic patterns, with 40 to 47% as the 4′-hydroxy metabolite, 5% as the 3′,4′-dihydroxy metabolite, 20 to 30% as the 3′-hydroxy- 4′-methoxy metabolite, and the remaining 20 to 25% of the drug being excreted unchanged. None of these metabolites demonstrates significant anti-inflammatory activity.
Clinical Use
Flurbiprofen is indicated as an oral formulation for the acute or long-term treatment of rheumatoid arthritis and osteoarthritis and as an ophthalmic solution for the inhibition of intraoperative miosis.
Flurbiprofen Preparation Products And Raw materials
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| ANWITA APIS | +919000311012 | Hyderabad, India | 195 | 58 | Inquiry |
| AVD pharmaceuticals Pvt Ltd | +919860835260 | Pune, India | 102 | 58 | Inquiry |
| GMFC LABS PVT LTD | +91-9133370278 +91-9133370278 | Hyderabad, India | 44 | 58 | Inquiry |
| PANCHSHEEL ORGANICS LTD | +91-9821053955 +91-9324201019 | Mumbai, India | 82 | 58 | Inquiry |
| FDC Limited | +912226782653 | Mumbai, India | 30 | 58 | Inquiry |
| Integrin Life Sciences. Pvt. Ltd. | +91-4040265469 +91-9849990870 | Hyderabad, India | 90 | 58 | Inquiry |
| Venture Pharmaceuticals pvt ltd | +91-9173909075 +91-9173909075 | Gujarat, India | 45 | 58 | Inquiry |
| Vanquest Pharma Pvt Ltd | +91-9920897640 +91-9920897640 | Mumbai, India | 36 | 58 | Inquiry |
| Sreepathi Lab Pvt Ltd | +91-9394118626 +91-9394118626 | Telangana, India | 9 | 58 | Inquiry |
| Eiko LifeSciences Ltd | +91-02225438095 +91-02225438095 | Mumbai, India | 26 | 58 | Inquiry |
| Supplier | Advantage |
|---|---|
| ANWITA APIS | 58 |
| AVD pharmaceuticals Pvt Ltd | 58 |
| GMFC LABS PVT LTD | 58 |
| PANCHSHEEL ORGANICS LTD | 58 |
| FDC Limited | 58 |
| Integrin Life Sciences. Pvt. Ltd. | 58 |
| Venture Pharmaceuticals pvt ltd | 58 |
| Vanquest Pharma Pvt Ltd | 58 |
| Sreepathi Lab Pvt Ltd | 58 |
| Eiko LifeSciences Ltd | 58 |
Related articles
- Flurbiprofen: Synthesis and Application
- Flurbiprofen has been used at 150 ~ 300 mg/d in the treatment of rheumatoid arthritis, osteoarthritis, and ankylosing spondyli....
- Mar 16，2024